Activation of KCNQ channels prevents paclitaxel-induced peripheral neuropathy and associated neuropathic pain

Paclitaxel is a commonly used chemotherapeutic agent for the treatment of breast and other cancers12. Unfortunately, its use is often associated with significant neurotoxicity, especially resulting in sensory peripheral neuropathies that are often accompanied by neuropathic pain and are frequently severe and resistant to intervention. Paclitaxel-induced peripheral neuropathy (PIPN) results from damage to, or dysfunction of, peripheral nerves, including sensory, autonomic, and motor neurons. The incidence and severity of PIPN is duration- and dose-related, such that more than 60% of patients receiving paclitaxel-based chemotherapy experience peripheral neuropathy in first 3 months58.

from The Journal of Pain https://ift.tt/2PHpGnG
via IFTTT